Re: Farmas USA
Novavax initiated with an Overweight at JPMorgan
JPMorgan says it is impressed by the potential of Novavax's proprietary recombinant nanoparticle vaccine technology. The firm started shares with an Overweight rating and $7 price target.
Un PO conservador.
NVAX